Cervical cancer remains the third most common cancer in women worldwide, with approximately 529,800 new cases and 275,100 deaths annually [1, 2]. Of note, incidences of cervical cancer are disproportionally distributed between developed countries and less-developed countries [3] (Figure 1). Cervical cancer incidence rates and deaths in well-developed countries have progressively declined [4] (Figure 2), due to cancer screening programs and HPV vaccination programs funded by huge government budgets [5]. In less-developed countries [6, 7], however, cervical cancer is still one of the most prevalent cancers and the leading cause of cancer deaths in women, many of whom are often diagnosed at an age when they are still raising families. For example in China, a significantly increasing incidence and mortality trend are observed for cervical cancer, especially in young women [7]. Cervical cancer has become the second most common female cancer and the third leading cause of cancer deaths in China.
women aged 15 to 44 years [8]. In India, cervical cancer ranks as the second leading cause of cancer in women. An estimated one-fourth of the world’s cervical cancer deaths every year (~77,100) occur in the second most populated country in the world [8, 9]. It is worth noting that in recent years, due to the lack of effective prevention/screening methods, incidences of cervical cancer are still increasing in developing countries [3, 10].

HPV infection is recognized as a major causative factor in the development of cervical cancer [11]. Epidemiological research shows that in sexually active women, the viral infection rate might be as high as 80% [12]. While most
of the viral infections are cleared spontaneously by host immunity, a very few persist and eventually cause cancer [13]. Thus, cervical cancer is a rare accident in common HPV infections [14]. Currently, there is no effective treatment for HPV persistence [15]. Prevention of HPV-related cervical cancer relies on costly HPV vaccines and repeated cervical screenings [16]. Although vaccines have shown promising results in recent years [17], the implementation of universal HPV vaccination strategies is expensive for developing countries [5, 18], especially for populous countries such as China and India, and the multivalent vaccines cannot completely cover all the major types of HPV infections in these countries [19]. In addition, all commercially available vaccines are prophylactic, and they have no therapeutic effects on existing infections [15]. For unvaccinated HPV-infected patients who are still at risk for cervical cancer, repeated screenings and colposcopy-directed biopsies are performed. Consequently, these interventions have given rise to potential overtreatment, additional costs, patient anxiety, and adverse effects (e.g., vaginal bleeding and impaired sexual function) [20, 21]. Due to the huge economic burden posed by cervical screening and vaccination programs, many women in both developed and developing countries are still unprotected from HPV infections and its related cervical cancers [10].

**Key Factors that Contribute to HPV Persistence and Cervical Carcinogenesis: Host Susceptibilities to Latent HPV Infections and Cervical Cancer**

Like many other types of malignancies, cervical cancer is a chronic complex disease caused by a combination of inherited genetic factors and external environmental influences [22, 23]. As a major environmental risk factor, HPV infections on their own have been discovered to be insufficient to cause cancer [24]. This notion is supported by the phenomenon that 60% of HPV infections regress spontaneously within 1 year and 90% regress within 2 years [25], leaving very few cases that may harbor intrinsic susceptibility for progressing to precancer or cancer. Therefore, efforts to identify inherited genetic risk factors are of great value [26], as they will provide more insights into host–virus interactions [27] as well as an overall etiological understanding of cervical carcinogenesis [22, 28]. Obvious evidence of genetic factors contributing to cervical carcinogenesis can be proved by warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome (WHIM) and hereditary nonpolyposis colorectal cancer (Lynch) syndrome, two autosomal dominant genetic disorder characterized by extensive HPV infection and high risk of cervical cancer [29, 30].

Previous researches on host susceptibility to cervical cancer have focused on the genes that are involved in the human leukocyte antigen (HLA), which is also known as the major histocompatibility complex (MHC) system [31]. The system encodes particular antigens to stimulate the multiplication of T helper cells and activates a series of immune reactions to clear that specific antigen [32]. The first study that discovered these common variants in the MHC system was conducted in the 1990s, when an increase in relative risk for cervical cancer was seen for DQB1*0303 and DQB1*0604, and a decrease in relative risk was seen for DQB1*0201 and the heterozygote DQB1*0301/*0501 in African-American women [33]. Interestingly, only a few months later, another study conducted with Norwegian patients also report similar susceptible loci DQA1 and DQB1 in the MHC region, with partial but not complete overlap [34]. From then on, many more variants of MHC genes were discovered and confirmed to be correlated with cervical cancer in various populations [35–39]. Wu et al. [37], confirmed that the HLA-II DQB1*0602 allele was significantly increased in HPV16-infected patients with cervical cancer. Jia et al. [36], found three HLA-DP SNPs (rs4282438, rs3117027, and rs3077) to be significantly associated with the risk of cervical cancer. The MICA gene, which is located at the MHC I region on chromosome 6p21.33, is another research hotspot for cervical cancer susceptibility. Chen et al. [39] conducted a genomewide association study (GWAS) of cervical cancer in the Swedish population and identified three independently acting loci within the MHC region: rs2516448 (class I region in proximity to MICA), rs9272143 (class II region between HLA-DRB1 and HLA-DQA1), and rs3117027 (class II region at HLA-DPB2). To date, the largest investigation on host susceptibility to cervical cancer has been carried out in the Chinese population [22]. The investigation initially included 1364 individuals with cervical cancer (cases) and 3028 female controls, and was followed by two independent validation cohorts (1824 cases and 3808 controls for validation 1 and 2343 cases and 3388 controls for validation 2). Nine significant SNPs were identified within a 180-kb region that includes HLA-DPB1/2 and HLA-DPA1. Together, these association analyses strongly suggest important involvement of HLA alleles or the host innate immune system in the tumorigenesis of cervical cancer. However, unlike cervical cancer, MHC-associated study for precancer reported rarely met GWAS level and non-MHC researches need to promote for GWAS significance.

Additional studies also reported the potential roles of common gene variants that are involved in the cellular cycle and apoptosis, cell proliferation and differentiation, DNA repair, and immune responses [40–46]. Nevertheless, as in many other association analyses, evidence of how
genetic susceptibility is linked mechanistically to the progression of cervical cancer is still lacking. Therefore, post-GWAS functional studies (i.e., genetically modified cell lines or mice created by CRISPR) are urgently needed to understand the possible mechanisms of genetic susceptibility to cervical cancer.

**Major Genetic and Epigenetic Events during the Interplay Between HPV and the Host**

**HPV variants and cervical cancer**

Human papillomaviruses are a big family with the systematic classification of five genera (α, β, γ, μ, and ν), 48 species, and 206 types [47]. The contribution of HPV types to cervical carcinogenesis is different, and responsive classification related to oncogenic degree contain 13 high-risk (HR) HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; IARC Group 1 & 2A), 14 possibly high-risk types (HPV 5 and 26, 53, 66, 67, 68, 70, 73, 82, 30, 34, 69, 85, and 97; IARC Group 2B), and other low-risk types (HPV 6, 11, 42, 44, etc.; IARC Group 3) [48]. Among the HR HPV types, HPV16 accounted for more than half of the cervical cancer in the world, while HPV18 making up 16.5% as the second most carcinogenic type [49].

In addition to HPV genotypes, HPV intratype variants also have epidemiological and oncogenic value in cervical cancer. Based on whole-genome comparison, HPV16 variants have four major lineages: A, including A1–3 (European), and A4 (Asian) sublineages; B (African 1); C (African 2) and D, including Asian American (AA) and North American (NA). In the same way, HPV18 variants have been defined into three major lineages (A, B, and C) and additional sublineages (A1 to A5 and B1 to B3) with translation [A1 and A2 = AA (Asian Amerindian), A3 to A5 = E (European), and B/C = AFR (African)] [47].

According to the largest to date oncogenic risk analysis of HPV16 sublineages at Kaiser Permanente Northern California, A4, C, D2, and D3 had higher risk of cervical precancer and cancer compared to extensive A1/A2 sublineages [50]. In accordance with this study, a recent meta-analysis has demonstrated that A lineage accounted for a majority of Asian HPV16 variants, and A4 sublineage was more oncogenic than A1-3 in China [51]. Interestingly, contradictory conclusion was drawn that amino acids of HPV16 E7 shared highly conservation among different sublineages in cervical malignancy by deep sequencing of HPV genome region [52]. This study suggests that E7 is the key of HPV16-related carcinogenesis regardless of viral sublineages. Further investigation on virus–host interaction pattern is also warranted to discover the exact targets for clinical triage and intervention.

In contrast to HPV16, a worldwide study revealed that HPV18 sublineages showed no significant association with cervical cancer risk or histological types [53]. However, a previous study in Spain reported that sublineage B had higher oncogenic risk compared to A sublineage but suffered from small sample sizes [54].

Besides, to provide comprehensive guidance for clinical application, it is worth further research that how oncogenic difference among HPV intratypes was influenced by ethnic genome variability, and geographical or behavioral factors.

**HPV integration**

Integration of the HPV genome into the host chromosome is a key genetic step in cervical carcinogenesis [55]. Numerous studies have shown that integration of HPV normally involves breaking up the open reading frames of viral E1 and E2 regions, resulting in the upregulation of oncogenes E6 and E7 [56]. E6 and E7 each has multiple cellular targets that promote malignant transformation. For instance, E6 binds and degrades tumor suppressor p53 and pro-apoptotic protein BAK, thereby increasing host cell resistance to apoptosis and permitting viral DNA replication [11, 57]. On the other hand, E7 inhibits tumor suppressor retinoblastoma 1 (RB1) to release E2F transcription factors, and stimulates cyclin-dependent kinase 2 (CDK2)/cyclin A [58] as well as CDK2/cyclin E complex [59], thus abrogating cell cycle arrest and stimulating proliferation [60].

The first experiment to identify HPV integration in the human genome was published in 1987, when a single copy of HPV16 was detected in the intergenic region between KLF5 and KLF12 on chromosome 13q22 in the SiHa cell line [61]. Since then, many PCR-based detection methods have been developed to explore the genomic interaction between the virus and the host. For instance, ligation-mediated chain reaction (DIPS-PCR) [62–69] and restriction site-PCR (RS-PCR) [63, 70–73] were used to profile HPV integration sites on the DNA level, while the amplification of papillomavirus oncogene transcripts (APOT) assay was used on the RNA level [62, 65, 74–80]. Although these methods were generally labor-intensive and time-consuming, the data lay the foundation for the understanding of the HPV integration pattern and its role in cervical carcinogenesis. The major conclusions of the early studies were a) HPV integration sites were distributed randomly on the host genome [81], b) but somehow still show a tendency toward common fragile sites in the genome [73] c) or are more prone to integrate into actively transcribed or easily accessible regions [55]. However, the...
integrated HPV genome was considered only as a disruption of E1/E2 for continued expression of the E6 and E7 oncogenes, but not as having an impact on the integrated genome of the host [62, 74, 82]. As evidence accumulated, an emerging point of view that the integrated virus can provide or exert selective advantage over nonintegrated clones began to gain supports [73, 83, 84]. Peter et al. showed that HPV integrated at chromosome 8q24 could lead to amplification and overexpression of downstream oncogene MYC [84]. This conclusion was later confirmed by the high-throughput haplotype study of HeLa as well as our genomewide study [85]. Another interesting report was published by Schmitz et. al., who demonstrated the correlation between HPV insertional mutagenesis, and loss of CASZ1 and LIPC gene function [86]. Generally, the integration sites detected by PCR-based experiments suffered from bias toward restriction sites in the human genome or the early gene of the HPV genome [28]. Although necessary and valuable, the data provided only a limited prospect about the whole picture of HPV integration-driven tumorigenesis.

With the development of next-generation sequencing, genomewide profiling of HPV integration sites is becoming feasible and cost-effective [87]. Technical advancements allow researchers to perform highly sensitive HPV integration analysis in larger samples, shedding new light on the underlying mechanisms of HPV integrations. In 2013, Xu et. al. published a novel multiplex strategy named TEN16 for sequence determination of HPV16 DNA integration sites based on next-generation sequencing, making the concomitant analysis of HPV16 integration sites in a single mixture of about 50 tumor samples possible [88]. Based on the experiment, the author suggested that a unique HPV integration breakpoint could serve as an attractive personalized tumor biomarker for prognostic evaluation and treatment of patients with cervical cancer. Akagi et. al. performed WGS on 10 HPV-positive cancer cell lines and presented a model of “looping” by which HPV integrant-mediated DNA replication and recombination may result in viral-host DNA concatamers, frequently disrupting genes involved in oncogenesis and amplifying HPV oncogenes E6 and E7 [89]. Our groups also analyzed HPV integration breakpoints in 26 cervical intraepithelial neoplasia, 104 cervical carcinomas, and five cell lines. Microhomologous sequence between the human and HPV genomes was significantly enriched near the integration breakpoints, indicating that fusion between viral and human DNA may have occurred by microhomology-mediated DNA repair pathways [28]. One year later, Allyson et al. developed a generic and comprehensive capture-HPV method followed by next-generation sequencing (NGS) as well [90]. Interestingly, the analysis of 72 cervical carcinomas identified five HPV signatures, and cross-analyses between the HPV signatures and the clinical and virological data revealed unexpected biased representation with respect to the HPV genotype, patient age, and disease outcome, suggesting functional relevance of this new classification.

DNA mutation of the host genome

In addition to HPV integrations into the human genome of the host genes, somatic mutations of the host genome during HPV-induced carcinogenesis have also been an important aspect of studying cervical carcinogenesis. DNA mutations analysis plays an important role in identifying differences between cancer tissue and noncancer tissue, and in guiding diagnostic and therapeutic regimens.

To date, the most comprehensive genomic landscape paper was published in Nature Journal; using NGS analysis, it revealed both known and novel high frequent mutations. The authors showed that the common mutations in SCC were EP300 (16%), FBXW7 (15%), PIK3CA (14%), HLA-B (9%), and p53 (9%) while PIK3CA (16%), ELF3 (13%), KRAS (8%), and CBFB (8%) were in ACC [91]. Of note, driver mutations in oncogenes HLA-B, EP300, and FBXW7 were newly identified in cervical cancers [91].

Besides these novel driver mutations, some important common mutations including the oncogenes PIK3CA, EGFR, KRAS, and the gene suppressor PTEN, p53, STK11, and MAPK genes [92–97] have already been reported in earlier genetic studies of the polymerase chain reaction (PCR) and Sanger sequencing [96, 98–100] or spectrometry-based mutation analysis [101, 102]. With the improvement of NGS assay, many researchers also have confirmed the above findings in different cervical cancer samples from different populations [103].

An important application of particular genomic mutations is that they may act as potential early screening biomarkers of cervical cancer. Therefore, numerous studies have explored the somatic mutations spectrum in CINs to cervical cancers and found potential early diagnostic gene mutation markers, such as oncogene EGFR, and PIK3CA, and the gene suppressors TP53 and PTCH1 [104–106]. Several other tumor suppressor gene mutations have also been reported in both cervical intraepithelial neoplasms and cervical cancers. LOH11CR2A/E124/CHEK1 are the receptors of SLIT and are involved in neural axis formation and angiogenesis. In CIN, the mutation frequency of CHEK1, E124, LOH11CR2A, RASSF1A, PTCH1, and PIK3CA is 28%, 21% [107], 15% [107], 26% [108], 1.5% [97], and 2.4% [105], respectively. Meanwhile, the mutation frequency of CHEK1, RASSF1A, E124, PIK3CA, and LOH11CR2A increased to 51% [107], 50% [108], 41% [107], 37.1% [105], and 36% [107] in cervical cancers, respectively. Chakraborty mentioned that the deletion
of PTCH1 gene was 42% in FIGO stage I/II [97] and 46% in stage III/IV [97]. Besides the common genomic mutation event, Goia-Rușanu et al. also found an interesting phenomenon, in that the D-loop region mutation in mitochondrial DNA also existed differently in different cytology status [109]. No mutations were detected in either normal or ASCUS cytology state, but an increasing rate of mutation detection was found in LSIL, HSIL, and SCC cases [109].

Studies also showed that gene mutations can have an impact on the prognosis of cervical cancer. CHEK1, E124, PTCH1, and ATM belong to the PI3/PI4-kinase family, and the tumor suppressor gene CADM1 is a predictor of the worst prognosis [97, 107, 110]. ATM and CADM1 can predict early invasiveness [110]. The PIK3CA mutation can decrease the distant metastasis rate [111]. PIK3CA mutation in 771 Chinese patients treated with surgery-based comprehensive therapy significantly improved the 3-year recurrence-free patient survival rate [111]. Moreover, studies have also illustrated that patients with KRAS mutations experienced an obvious declining recurrence-free survival rate [112].

DNA methylation of cervical carcinogenesis

Another prevalent epigenetic mechanism during HPV-induced carcinogenesis is DNA methylation, which is a methyl (-CH3) covalent addition to cytosine in the DNA sequence known as CpG dinucleotide [3]. CpG can accumulate in the CpG island, which is a CpG-rich sequence that is often located in the gene promoter [113]. During the progression of a malignancy, local hypermethylation of the CpG islands in the promoter regions of the downstream tumor suppressor genes can lead to their downregulated expression [114].

As exogenous pathogen, HPV epigenomic pattern has been thought to have prominent significance. Although the CpG islands on HPV genome are underrepresented, high density of CpG sites and characterized difference in E2/E4 region and alpha 9/7 clades still exist, indicating the underlying value of HPV DNA methylation mechanism [115, 116].

To identify specific methylation alteration of HPV DNA, bisulfite-based methylation-specific PCR (MS-PCR) and sequencing were used and demonstrated hypermethylation of LCR region of HPV 16 correlated with oncogenic progression in cell lines and cervical lesion [117]. With pyrosequencing method, cervical carcinogenesis was found related to the methylation of L1, L2, and E2/E4 region in HPV16 genome [118]. Another whole-genomewide pyrosequencing of HPV18, HPV31, and HPV45 revealed significantly elevated DNA methylation level in E2, L1, and L2 region in cervical intraepithelial neoplasia grade 3 (CIN3 + ) than transient infection [119]. As this research suggested, HPV methylation may serve as potential malignancy biomarker to distinguish the transforming infection. With NGS-based analysis of HPV16 CpG methylhaplotypes, a study testified the diagnostic effect of hypermethylation of E2, L1, and L2 region for CIN 3 + patients [120]. Recently, a targeting and methylation deep sequencing method reported that global HPV methylation level detects >95% ICC in HPV16 positive samples, specifically, with L1 as best marker for 13 HPV types and E1 as novel marker associated with HPV 16 [121]. However, the mechanism of HPV DNA methylation as biased molecular for HPV persistence and cervical cancer progression is not fully understood, which also strongly suggests further dedication to virus–host interaction research.

Besides, high-risk HPV E6 and E7 are directly related to functions of DNMTs (DNA methyltransferase), which are the key enzymes responsible for DNA methylation [122]. Further research of HPV-related methylation showed downregulation of E6- and E7-reduced methylation of tumor suppressor genes, thereby reversing the malignant phenotype of cervical cancer cells [123]. This evidence indicates that HPV oncogenes are related to host gene methylation.

In accordance with the data, DNA methylation was found to be a common event in cervical carcinogenesis. The level of methylation was positively correlated with the severity of both CINs and cervical cancer. Hesselink and Bierkens developed an objective nonmorphological molecular method of CADM1/MAL methylation as a cervical cancer screening marker with high sensitivity (ranging from 100% to 60.5%) for CINIII and patients with cervical cancer [124, 125]. Meanwhile, using a multiplex quantitative methylation-specific PCR, a recent study found a good concordance (78%) of CADM1/MAL methylation in biopsy results. The positive detection rates of gene methylation were 5.5% in normal biopsies, 63.3% in CIN3, and 100% in cervical cancer, respectively [126]. In two independent cohorts of patients with cervical cancer (n = 149, n = 121), using Illumina 450K methylation arrays, Lando indicated that promoter methylation events at 3p11-p14 could become a positive progression marker and a prognostic marker for cervical cancer [127]. Further studies on the functional research of these genes, including tumor inducer gene STK31, tumor suppressor PTCH1, and PTPRR indicated these methylation markers could be used in cervical screening to predict poor prognosis of the precancerous lesions [97, 128, 129]. In an analysis of promoter methylation of the PTEN gene using methylation-specific PCR, the data showed that methylation of the PTEN promoter was detected in 61% of the specimens. There was a positive correlation between PTEN methylation and the FIGO stage [130]. Low frequency (14–16%) of PTCH1
methylation was seen in the asymptomatic exfoliated cervical cells and in the normal epithelium adjacent to the tumor, followed by a significant increase in CIN (31%) in stage I/II (57%) and comparable CIN in stage III/IV (58%) [97]. The methylation frequency is also different in pathological classification. The hypermethylation of the candidate tumor suppressor gene, RASSF1A, was detected in 30% of SCC and 12% of AC, while it was absent in all normal tissues [131].

All above showed that altered DNA methylation pattern of high-risk HPV types and host genome has the potential application in the risk-based cervical cancer screening and diagnose, suggesting further study involving large-scale population experiment to test the effect.

**Molecular subgroups of cervical cancer**

Along with accumulation NGS data of cervical cancer, molecular characterization of different levels from genome to metabolism becomes gradually clear. However, achieving management of NGS data by integrative analysis proposes huge challenge but inevitable task to classify virus-induced carcinogenic subgroups by comprehensive molecular features, which is the guidance of ultimate clinical application of unbiased NGS strategy.

Recently, the Cancer Genome Atlas Research Network conducted a multi-omic analysis of invasive cervical cancer on 228 extended samples [132]. It combines multiple platforms including whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA-seq, microRNA-sequencing (miRNA-seq), DNA methylation profiling, and reverse phase protein array (RPPA) to classify molecular subtypes of cervical cancers [132]. Generally, this research defines three clusters keratin-low squamous, keratin-high squamous, and adenocarcinoma rich with different molecular features mainly based on mRNA expression analysis [133]. And for the first time, this study predicts endometrial-like (UCEC-like) cancers with ARID1A, KRAS and PTEN mutated, low copy number, low CpG island hypermethylated (CIMP-low), and RPPA hormone-associated features [132]. As for high-risk HPV-related carcinogenesis, it first reports type-associated molecular signature except integration [133].

Of note, the most important value of this article is the intention of serving clinical translation and reasoning. By structural variation analysis, the TCGA researchers identified BCAR4, CD274 (PD-L1), and PDCD1LG2 (PD-L2) linked rearrangement events. PD-L1 and PD-L2 are two important immune checkpoints as well as promising immunotherapy targets [132]. Furthermore, the integrative analysis revealed >70% genomic alterations in either PI3K-MAPK or TGFβ pathway, also indicating potential therapeutic agents [132]. Besides, other contribution of this paper includes five new hypermutated genes and strong correlation of APOBEC somatic mutation [132].

In summary, with epigenomic and genomic data on cervical cancer and precancers being accumulated, a fundamental ground for the molecular classification of any HPV-associated carcinogenesis has been established, as well as personalized biomarkers for each stage [134]. However, we need further research to better understand the molecular subclassification of cervical lesions and, more important, develop precision medicine for patient diagnose and treatment [135].

**New Concepts and Technologies for Early Prevention and Treatment of Cervical Cancer**

**Current primary and secondary prevention of cervical cancer**

Pap cytology has brought up as standard secondary cervical cancer screening for more than half a century, with standardized evaluation Bethesda System established in 1988 and other modified technique like liquid-based cytology (LBC) and process automation developed in 2000s [136–138]. Undoubtedly, nationwide coverage and high-quality Pap test significantly reduced at most 80% mortality of the cervical cancer in developed countries (International Agency for Research on Cancer, released on 3 May, 2004). At the meantime, as the role of high-risk HPV in cervical carcinogenesis fully understood and existence detected in exploited cervical cell sample in 1990s, molecular test of HPV DNA was gradually acknowledged as more sensitivity tool than Pap test alone. At first, HPV test was advised for alternative triage of patients with abnormal cytology results before 2003. Along with the increasing attachment of HPV infection especially high-risk HPV types and mature of detection method, alternative cotesting of HPV and Pap smear was introduced as well as HPV genotyping [139]. However, the positive effect of HPV test alone was not affirmed, which stimulated amounts of clinical trials such as Indian trial in 2009 and Addressing the Need for Advanced HPV Diagnostics (ATHENA) trial in 2014 to encourage approval of HPV test alone as primary screening strategy [140, 141]. At the same year of ATHENA trial finished in the United States, The Food and Drug Administration (FDA) approved the first HPV test for primary cervical cancer screening [142]. In 2015, an interim guideline, later a new cervical cancer screening and prevention Practice Bulletin published, recommended HPV genotyping test alone as primary screening combined with cytology triage, which has been implemented in some developed countries [143, 144].
However, given that HPV test is accompanied by high false positive, the unavoidable increasing consequences of referral to colposcopy would bring psychological side effect and downstream overdiagnosis and overtreatment. Besides, in developing country where >80% cervical cancer incidence was observed, the screening strategy was not performed the best effect due to complex reasons including socioeconomic disparity, low screening coverage and limited funding of government, high personal cost and lack of related health knowledge and crucially, low quality of screening services, and unsound follow-up management [145, 146]. On the other hand, in developed countries, repeated screening program has posed huge economic burdens on the government budget and psychosomatic pressure on healthy women in the program. All above suggest that successful as the current screening strategy is, improvement still needs for the risk-stratified screening program.

Novel screening strategies of cervical cancer in development focus on the utility of biomarkers and other molecular tests on account of the objectivity and reliability, including p16/ki67, E6/E7 mRNAs, microRNAs, and methylation of HPV and host genome [147]. However, none of these tests could predict the potential population that will have persistent HPV infection and progress to cervical cancer, which is personalized associated with host susceptibility, environmental factors, and behavioral pattern besides HPV infection. This arises many related researches to improve current screening efficacy. Instead of one-size-fits-all program, a risk stratification model with bioinformatic methods was made to take full advantage of screening history of patients [148]. Besides, a previous paper reported that multiple regression assay and simple artificial learning algorithm achieved high sensitivity and specificity effect to predict cervical cancer [149]. These studies indicate that research involving large-scale population, dynamic bioinformatic tools, and comprehensive information is worthy of further conduction to create a personalized risk prediction model of HPV persistence and cervical carcinogenesis.

Except for HPV test, followed great invention was prophylactic HPV vaccine approved in 2000s. The FDA has approved bivalent vaccine Cervarix against HR-HPV16/18, responsible for 70% cervical cancer, quadrivalent vaccine Gardasil preventing infection with HPV6/11 added and 9-valent vaccine Gardasil9 against additional five types 31, 33, 45, 52, and 58. The primary prevention of HPV-related cervical cancer with HPV vaccine was strikingly promising and many countries have in succession initiated the national immunization program for girls aged 9-25 before sexual behavior onset. However, with the vaccinated girls reaching screening age, the current prevention and screening guideline is not fully ready for the differentiation between who has been HPV-vaccinated and who has not. A recent study using model-based analysis suggested that for HPV-vaccinated women, the screening should start later, take place less frequently and involve primary HPV testing rather than cytology, much different from current guideline routines [150]. Unanimously, an Italian study reported that the tailored screening protocol for HPV-vaccinated women should start at 30 with HPV test and have longer intervals of rescreening for HPV-negative results, which still needed further research to determine [151].

**Current HPV testing methods for cervical screening**

As persistent infection with high-risk types of human papillomavirus (HPV) is a necessary condition for cervical carcinogenesis, in recent years HPV detection has gradually become the primary screening method for cervical cancer, instead of cervical cytology. The development of HPV tests is still growing rapidly. To date, at least 193 different HPV tests are available for the detection of HPV in cervical specimens [152]. However, of these tests, only 110 (57%) have been cited more than once in the literature, and only 69 (35.7%) have been analyzed or clinically evaluated in publication [152]. Solid clinical data are urgently needed to evaluate the efficacy of new techniques.

The Hybrid Capture 2 (HC2) HPV DNA test has been widely adopted to determine HPV infections and to detect HSIL and cervical cancer. Generally, sensitivities for detection of CIN2 or greater ranged from 84.9% to 100%, and specificities ranged from 69.5% to 95.8% [153]. The Cervista HPV HR test was approved by the FDA in 2009. A number of clinical trials reported that the Cervista HPV HR test could more accurately detect high-risk HPV compared to the HC2 test and may have the advantage to lower the cross-reactivity to other HPV types [154–156]. Two years later, the Cobas 4800 HPV test was FDA approved in 2011. Clinical studies showed that the Cobas test’s sensitivity was comparable to that of the HC2 test, but the Cobas test had improved specificity because it has a lower level of cross-reactivity with other low-risk HPV types [157–159]. However, false-negative results may occur because the L1 gene is lost when the virus integrates into the host genome in a substantial number of patients [160].

Recently, detection of the HPV E6/E7 oncogene mRNA has become an alternative to the HPV DNA test. Studies show that little expression of E6/E7 mRNA may be detected in transient infections, but in persistent infections, E6/E7 mRNA is overexpressed. Therefore, detection of upregulated expression of E6/E7 mRNA can be directly related
Potential future for NGS-based HPV testing

To date, there are numerous HPV tests, including PCR-based MY09/11 and CPI/II systems [162], the hybridization-based SPF LiPA method; signal-amplification assays (Hybrid Capture 2 and Cervista); and nucleic acid-based amplification-like microarray and real-time PCR-based methods (the Cobas 4800 real-time test) [162–164] (Figure 3). These techniques seemed to perform well, but still may have many limitations, for example difficulty in detecting minor and low-abundance HPV types, or a mixture of coinfections [165, 166]. More important, this generation of screening methods could not detect the integration status of the virus, which is a key genetic event in the development and progression of cervical cancer. In recent years and in the near future, emerging new technologies of NGS have the potential to overcome such limitations. There have already been investigations using TEN16 or HIVID methodology to determine coinfection among the HPV types as well as HPV integration sites in the human genome [28, 88, 167–169]. Therefore, future possible applications of NGS-based HPV screening include (i) determination of HPV integration sites in the human genome for risk stratification, (ii) precise detection of HPV types in cervical lesions, (iii) epidemiological monitoring of both low-risk and high-risk HPV type distribution, and (iv) discovery of new HPV genotypes.

However, data of NGS-based HPV testing are still lacking, and the technology clearly has both advantages and disadvantages. First, with the knowledge that the NGS-based HPV test is highly sensitive, the data of this method must be interpreted with care, because high sensitivity also means a high false-positive rate and possible overtreatment of patients. Second, costs and turnaround time are the major problems with diagnostic methods based on NGS technologies [172]; however, with the development of new techniques, both the price and the length of time needed to perform NGS-based tests are dropping.
drastically. And as for the interpretation, there is emerging software to detect infected virus types and more importantly, virus integration status and specific region based on chimeric reads and other algorithms. Although software could obtain high sensitivity and specificity detection effect in diverse NGS data of virus-related (HBV, HPV, and EBV) cancer, including whole-genome sequencing, targeted sequencing, and RNA-seq [167, 173–179], there is still great challenge in applying to clinical practice. Given the complex variation induced by HPV integration, most software has common problem in standardization under different circumstance and therefore still relies on the PCR-based Sanger sequencing to testify the accuracy. Importantly, for most users especially clinician, who do not possess bioinformatic knowledge and skills, the application is extremely restricted and accordingly the transforming period will be much longer.

Overall, it is quite possible NGS-based assay will become even more cost-effective than the classical HPV testing assays such as Cobas 4800. Nevertheless, full automation and standardization of protocols for library preparation and sequencing as well as user-friendly and mature interpretation tool are urgently required for the implementation of this technology in routine diagnostics [180].

**Immunotherapy of cervical cancer**

Along with the prevalence of HPV vaccination and cervical cancer screening, the treatment of early stage cervical disease also advanced, together will continue decreasing the incidence and mortality of cervical cancer [181]. However, for those patients who have invasive, advanced-stage or recurrent cervical cancers. Traditional treatment including systemic chemotherapy, surgery, and radiotherapy offers limited choices. These patients still suffer the great pain and insignificant survival rates brought by treatment and do not benefit from the research outcomes of interplay patterns between host and HPV during malignant progression. Although HPV is the key factor for causing almost all cervical cancers, the infection alone is not sufficient for malignancy of decades progression that inducing additional tumor-promoting steps needed, especially the evident evasion of immune surveillance [182]. Therefore, new paradigm such as immunotherapy provides promising opportunity for the treatment of HPV-driven carcinogenesis.

The current immunotherapy methodology with clinical trials undergoing or accomplished includes therapeutic vaccine (NCT02164461, NCT02291055, NCT01304524, NCT02172911, NCT02128126, NCT00988559, and NCT078164), targeted antibodies (NCT01778439, NCT00803062, and NCT01281852), T-cell immune checkpoint inhibitor (NCT01711515, NCT01693783, NCT0147121, NCT0174739, NCT02205333, and NCT01693562), and adoptive T-cell transfer (ACT; NCT01585428).

As a paper commented, the targeted therapies of cervical cancer revealed encouraging though limited effect [133]. For example, anti-VEGF antibody bevacizumab combined to chemotherapy improved 3.7 months in median overall survival of patients with advanced-stage cervical cancer [183]. So are clinical trials of other algorithms. Bacteria-vector vaccine ADXS11-001 without cisplatin was found no different survival outcome and tumor response but a safety profile compared to with cisplatin [184]. A phase-I study of ACT clinical trial has shown complete regression on two of nine metastatic cervical cancer patients but no overall survival influence reported, indicating that further investigation is warranted promisingly [185]. In addition, T-cell immune checkpoint inhibitor such as pembrolizumab targeting the popular PD-1-PD-L1 axis was found tolerant and promising in PD-L1-positive recurrent or metastatic cervical squamous cell cancer [186].

Overall, there are still modified immunotherapy researches and clinical trials in progress hopefully to improve the survival of the patients who have limited choices.

**Genome Editing Tools for Treatment of HPV Infections and Their Related Cervical Lesions**

Currently, there is no effective treatment for HPV persistence. Previous researchers (including those from our laboratory) have shown that targeting HPV E6/E7 mRNAs with siRNA could effectively knock down their expression and induce apoptotic cell death in HPV-positive cell lines. However, siRNAs only block HPV E6/E7 mRNAs temporarily, and they do not attack HPV DNA in the nuclei, which serves as a store of escape mutants that cause resistance to siRNA application. In recent years, artificially engineered genome editing techniques such as zinc finger nucleases (ZFNs), Tal-effector nucleases (TALENs), and the RNA-guided engineered nucleases (RGENs or CRISPR/Cas9) were used to cleave the specific DNA sequence of HPV. Generally, the double-stranded DNA breaks (DSBs) introduced by these custom-engineered endonucleases should trigger DNA repair pathways (NHEJ repair pathway in most of the cases), resulting in the disruption of target viral oncogenes and the elimination of HPV infections (Figure 4).

In the early stage of development of HPV-targeted genome editing tools, ZFNs were designed to disrupt the E6 or E7 genes of the high-risk HPV types 16 or 18. These reports showed ZFNs could disrupt HPV genomes in HPV-positive cell lines and in vitro culture models. Of note, one study demonstrated that injected ZFNs may...
even inhibit growth of HPV-positive tumor xenografts, implicating their potential as anticancer drugs. However, ZFNs also have some limitations. First, construction of ZFNs is very labor-intensive and may be hard to replicate in laboratories that do not have sophisticated skills molecular engineering skills. Second, the specificity of ZFNs varies greatly in different studies. Generally, the lengths of the recognition sequences are determined by the number of zinc fingers for the corresponding nuclease (often 18–24 nucleotides for 6 to 8 fingers). Although increasing the number of zinc fingers would improve their specificity comparable to that of the TALENs, extensive experiments would be required to screen the best combinations of ZFN monomers with different numbers of zinc fingers [187].

Another comprehensive study has demonstrated that TALENs as well as ZFNs can also be used as a therapeutic strategy to treat HPV-related cervical lesions. In the study, the author achieved comparable or better efficacy to cleave E6 and E7 genes of HPV-16 and HPV-18 using artificially engineered TALENs. Interestingly, through topical application of TALENs directly onto the cervix of the HPV-driven malignant phenotype of K14-HPV16 transgenic mice, cervical intraepithelial neoplasms regressed to normal cervical tissues. Mutations of the E7 gene and reduction in the HPV16 DNA load were further confirmed. One potential advantage of TALEN is that its longer DNA-binding sequence (approximately 30–40 nucleotides or more) may determine its improved specificity over clustered regularly interspaced short palindromic repeat (CRISPR) RNA-guided nuclease [187], ZFN, and siRNAs. On the other hand, the longer DNA-binding sequence of TALENs, as well as their larger backbone, could be difficult to pack into vehicles such as AAV or lentiviral delivery systems.

With the emergence of CRISPR, this widely adopted technique has also been developed to target the E6 or E7 genes of HPV types 6, 11, 16, or 18. The antiviral efficacy of CRISPR/Cas9 has been shown in a number of in vitro cell culture models and also in HPV-positive tumor xenograft models. Disruption of HPV E6 and E7 led to downregulation of their corresponding viral proteins and resulted in restoration of the tumor suppressor p53 and pRb. The primary concern of the CRISPR technique is its off-target effects when it is applied in human subjects. The specificity of the newly developed and RNA-guided CRISPR endonuclease is mainly determined by the protospacer adjacent motif (three nucleotides) and seed sequences (approximately 12 nucleotides), which are located at the 3′-end of its recognition sequence GN20GG [188]. The relatively short length of the CRISPR recognition sequence (approximately 14 nucleotides) makes the endonuclease more prone to produce undesired, off-target mutations in the human genome, thus limiting its further use in therapeutic applications [189]. Nevertheless, the specificity of the CRISPR system was recently improved by the paired RNA-guided, double-nicking strategy (approximately 28 nucleotides), or the modified high-fidelity versions of CAS9 [190].

Genome editing-based antiviral therapy may play valuable roles in HPV-related cervical carcinogenesis. If this therapy is appropriately combined with HPV testing, patients in precancerous stages, such as persistent HPV
infections and their related CINs, would be able to take HPV testing first to determine the HPV subtype(s) and then select the corresponding type-specific genome editing tools to treat the appropriate HPV infection(s) and their related precancerous diseases. These patients would benefit from this new “screen-and-immediately-treat” strategy, instead of potential overtreatment including repeated screenings, colposcopy-directed biopsies, and cold knife conization. Consequently, additional costs, patient anxiety, and adverse effects that can result from repeated screenings, colposcopy-directed biopsies, and cold knife conization (e.g., vaginal bleeding and cervical insufficiency) could be avoided.

In the future, more study still needs to be performed. When applied to human subjects, the length of time that the complexes need to stay resident in the vagina must be further determined; to extend this time, polymer-complexed artificially engineered nucleases could be directly applied to the anogenital tract using devices such as the CerviPrep drug delivery system [191] or they could be formulated into vehicles suitable for anogenital tract retention (e.g., suppository, gel, or cream)[192]. In addition, physiological changes of the vagina and cervix that occur with the menstrual cycle, particularly the pH value and vaginal fluid, should also be taken into consideration when artificially engineered nucleases are delivered intravaginally [193].

Future Directions and Conclusion

With the emerging new concepts and technologies for cancer interventions, the precise prevention, diagnosis, and treatment of cervical are not only necessary, but now [194]. The clarification of the molecular mechanism underlying HPV persistence and related cervical cancer will help us to predict the prognosis of patients with HPV infections at an earlier stage. Molecular classification based on HPV integration and genetic profiling may also translate into the precision medicine that allows clinicians to focus medical resources more on high-risk patients whose diseases are genuinely progressing, greatly reducing the psychological and economic burdens of the cervical screening programs and HPV vaccination programs in the future.

Online Method

Figures 1 and 2 were made online: http://gco.iarc.fr/today/online-analysis-map?mode=cancer&mode_population=continents&population=900&sex=2&cancer=16&type=1&statistic=0&prevalence=0&color_palette=default&projection=natural-earth#modalTakeATourVideo

Acknowledgments

This research was supported by funds from the National Basic Research Program of China (973 Program, No. 2015CB553903 to Ding Ma and No. 2013CB911304 to Hui Wang), 2015BAI13B05 the National Science-technology Supporting Plan Projects (2015BAI13B05), Chinese National Key Plan of Precision Medicine Research (2016YFC0902901), Nature and Science Foundation of China (81402158, 81472783, 81230038, 81372805).

Conflict of Interest

None declared.

References

1. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90.
2. Crosbie, E. J., M. H. Einstein, S. Franceschi, and H. C. Kitchener. 2013. Human papillomavirus and cervical cancer. Lancet 382(9885):889–99.
3. Allemani, C., H. K. Weir, H. Carreira, R. Harewood, D. Spika, X. S. Wang, et al. 2015. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010.
4. Siegel, R. L., K. D. Miller, and A. Jemal. 2016. Cancer statistics, 2016. CA Cancer J. Clin. 66:7–30.
5. Pogoda, C. S., R. B. Roden, and R. L. Garcea. 2016. Immunizing against Anogenital Cancer: HPV Vaccines. PLoS Pathog. 12:e1005587.
6. Bray, F., A. Jemal, L. A. Torre, D. Forman, and P. Vineis. 2015. Long-term realism and cost-effectiveness: Primary prevention in combatting cancer and associated inequalities worldwide. J. Natl Cancer Inst. 107:dv273.
7. Chen, W., R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, et al. 2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66:115–132.
8. Bruni, L., L. Barrionuevo-Rosas, G. Albero, M. Aldea, B. Serrano, S. Valencia, et al. 2014. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World Summary Report. 227.
9. Mallath, M. K., D. G. Taylor, R. A. Badwe, G. K. Rath, V. Shanta, C. S. Pramesh, et al. 2014. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 15:e205–e212.
10. Plummer, M., C. de Martel, J. Vignat, J. Ferlay, F. Bray, and S. Franceschi. 2016. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health. 4:e609–e616.
11. Zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342–350.
12. Chesson, H. W., E. F. Dunne, S. Hariri, and L. E. Markowitz. 2014. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex. Transm. Dis. 41:660–664.
13. Winer, R. L., J. P. Hughes, Q. Feng, L. F. Xi, S. Cherne, S. O’Reilly, et al. 2011. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol. Biomarkers Prev. 20:699–707.
14. Woodman, C. B., S. I. Collins, and L. S. Young. 2007. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7:11–22.
15. Hu, Z., W. Ding, D. Zhu, L. Yu, X. Jiang, X. Wang, et al. 2014. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J. Clin. Investig. 125(1):425–36.
16. Elfstrom, K. M., L. Arnhem-Dahlstrom, L. von Karsa, and J. Dillner. 2015. Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur. J. Cancer 51:950–968.
17. Skeate, J. G., A. W. Woodham, M. H. Einstein, D. M. Da Silva, and W. M. Kast. 2016. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum. Vaccin Immunother. 12:1418–1429.
18. Levin, C., M. Sharma, Z. Olson, S. Verguet, J. F. Shi, S. M. Wang, et al. 2015. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Pp. 295–306 in H. Gelband, P. Jha, R. Sankaranarayanan, S. Horton, eds. Cancer: Disease control priorities, Third Edition, Vol. 3. The International Bank for Reconstruction and Development / The World Bank, Washington, DC.
19. Zhai, L., and E. Tumban. 2016. Gardasil-9: A global survey of projected efficacy. Antiviral Res. 130:101–109.
20. Flanagan, S. M., S. Wilson, D. Luesley, S. L. Damery, and S. M. Greenfield. 2011. Adverse outcomes after colposcopy. BMC Womens Health. 11:2.
21. Graziottin, A., and A. Serafini. 2009. HPV infection in women: psychosocial impact of genital warts and intraepithelial lesions. J. Sex Med. 6:633–645.
22. Shi, Y., L. Li, Z. Hu, S. Li, S. Wang, J. Liu, et al. 2013. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat. Genet. 45:918–922.
23. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674.
24. Schiffman, M., P. E. Castle, J. Jereonimo, A. C. Rodriguez, and S. Wacholder. 2007. Human papillomavirus and cervical cancer. Lancet 370:890–907.
25. Moscicki, A. B., S. Shiboski, N. K. Hills, K. J. Powell, N. Jay, E. N. Hanson, et al. 2004. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364:1678–1683.
26. Dai, J., W. Shen, W. Wen, J. Chang, T. Wang, H. Chen, et al. 2016. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. Int. J. Cancer 140(2):329–336.
27. Lieberman, P. M. 2016. Epigenetics and genetics of viral latency. Cell Host Microbe 19:619–628.
28. Hu, Z., D. Zhu, W. Wang, W. Li, W. Jia, X. Zeng, et al. 2015. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat. Genet. 47:158–163.
29. Antill, Y. C., J. G. Dowty, A. K. Win, T. Thompson, M. D. Walsh, M. C. Cummings, et al. 2015. Lynch syndrome and cervical cancer. Int. J. Cancer 137:2757–2761.
30. Hernandez, P. A., R. J. Gorlin, J. N. Lukens, S. Taniuchi, J. Bohinjec, F. Francois, et al. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 34:70–74.
31. Gimenes, F., J. J. Teixeira, A. L. de Abreu, R. P. Souza, M. W. Pereira, V. R. da Silva, et al. 2014. Human leukocyte antigen (HLA)-G and cervical cancer immunodetection: a candidate molecule for therapeutic intervention and prognostic biomarker? Biochim. Biophys. Acta 1846:576–589.
32. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–264.
33. Gregoire, L., W. D. Lawrence, D. Kukuruga, A. B. Eisenbrey, and W. D. Lancaster. 1994. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int. J. Cancer 57:504–507.
34. Helland, A., A. L. Borresen, G. Kristensen, and K. S. Ronningen. 1994. DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. Cancer Epidemiol. Biomarkers Prev. 3:479–486.
35. Odunsi, K., G. Terry, L. Ho, J. Bell, J. Cuzick, and T. S. Ganesan. 1995. Association between HLA DQB1 *03 and cervical intra-epithelial neoplasia. Mol. Med. 1:161–171.
36. Jia, M., J. Han, D. Hang, J. Jiang, M. Wang, B. Wei, et al. 2016. HLA-DP is the cervical cancer susceptibility loci among women infected by high-risk
human papillomavirus: potential implication for triage of human papillomavirus-positive women. Tumour Biol. 37:8019–8025.
37. Wu, Y., Y. Chen, L. Li, Y. Cao, Z. Liu, B. Liu, et al. 2006. Polymorphic amino acids at codons 9 and 37 of HLA-DQB1 alleles may confer susceptibility to cervical cancer among Chinese women. Int. J. Cancer 118:3006–3011.
38. Ivansson, E. L., I. Juko-Pecirep, H. A. Erlich, and U. B. Gylensten. 2011. Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Genes Immun. 12:605–614.
39. Chen, D., I. Juko-Pecirep, J. Hammer, E. Ivansson, S. Enroth, I. Gustavsson, et al. 2013. Genome-wide association study of susceptibility loci for cervical cancer. J. Natl Cancer Inst. 105:624–633.
40. Gudleviciene, Z., J. Didziapetriene, M. Ramael, S. Uleckiene, and K. P. Valuckas. 2007. Integration of human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol. Oncol. 102: 530–533.
41. Assoumou, S. Z., A. L. Boumba, A. Ndjoyi-Mbiguino, A. Khattabi, and M. M. Ennaji. 2015. The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. Med. Oncol. 32:281.
42. Pina-Sanchez, P., D. M. Hernandez-Hernandez, L. Taja-Chayeb, R. M. Cerda-Flores, A. L. Gonzalez-Herrera, C. Rodea-Avila, et al. 2011. Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med. Oncol. 28:1507–1513.
43. Chattopadhayay, K., A. L. Williamson, A. Hazra, and C. Dandara. 2015. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer 15:680.
44. Kohaar, I., N. Thakur, S. Salhan, S. Batra, V. Singh, A. Sharma, et al. 2007. TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 29:249–256.
45. Zhuo, W. L., L. Zhang, J. J. Ling, Y. Zhu, and Z. T. Chen. 2012. MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals. Mol. Biol. Rep. 39:8723–8732.
46. Roszak, A., M. Lianeri, A. Sowinska, and P. P. Jagodzinski. 2014. CYP1A1 Ile462Val polymorphism as a risk factor in cervical cancer development in the Polish population. Mol. Diagn. Ther. 18:445–450.
47. Burk, R. D., A. Harari, and Z. Chen. 2013. Human papillomavirus genome variants. Virology 445:232–243.
48. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100:1–441.
49. Crow, J. M. 2012. HPV: The global burden. Nature 488:S2–S3.
50. Mirabello, L., M. Yeager, M. Cullen, J. F. Boland, Z. Chen, N. Wentzensen, et al. 2016. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J. Natl Cancer Inst. 108(9):djw100. https://doi.org/10.1093/jnci/djw100
51. Hang, D., Y. Yin, J. Han, J. Jiang, H. Ma, S. Xie, et al. 2016. Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. Virology 488:156–161.
52. Mirabello, L., M. Yeager, K. Yu, G. M. Clifford, Y. Xiao, B. Zhu, et al. 2017. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 170:1164–74.e6.
53. Chen, A. A., T. Gheit, S. Franceschi, M. Tommasino, G. M. Clifford, and Group IHVS. 2015. Human papillomavirus 18 genetic variation and cervical cancer risk worldwide. J. Virol. 89:10680–10687.
54. Perez, S., A. Cid, A. Inarrea, M. Pato, M. J. Lamas, B. Couso, et al. 2014. Prevalence of HPV 16 and HPV 18 lineages in Galicia, Spain. PLoS ONE 9:e104678.
55. Pett, M., and N. Coleman. 2007. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 212:356–367.
56. Zhang, R., C. Shen, L. Zhao, J. Wang, M. McCrae, X. Chen, et al. 2016. Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int. J. Cancer 138:1163–1174.
57. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79.
58. Arroyo, M., S. Bagchi, and P. Raychaudhuri. 1993. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol. Cell. Biol. 13:6537–6546.
59. McIntyre, M. C., M. N. Ruesch, and L. A. Laimins. 1996. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215:73–82.
60. Dyson, N., P. M. Howley, K. Munger, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937.
61. El Awady, M. K., J. B. Kaplan, S. J. O’Brien, and R. D. Burk. 1987. Molecular analysis of integrated human
papillomavirus 16 sequences in the cervical cancer cell line SiHa. Virology 159:389–398.
62. Ziegert, C., N. Wentzensen, S. Vinokurova, F. Kisseljov, J. Einenkel, M. Hoeckel, et al. 2003. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 22:3977–3984.
63. Raybould, R., A. Fiander, G. W. Wilkinson, and S. Hibbitts. 2014. HPV integration detection in CaSki and SiHa using detection of integrated papillomavirus sequences and restriction-site PCR. J. Virol. Methods 206:51–54.
64. Peter, M., N. Stransky, J. Couturier, P. Hupe, E. Barillot, P. de Cremoux, et al. 2010. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J. Pathol. 221:320–330.
65. Othnof, N. G., C. U. Huebbers, J. Kolligs, M. Henfling, F. C. Ramaekers, I. Cornet, et al. 2015. Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int. J. Cancer 136:E207–E218.
66. Matovina, M., I. Sabol, G. Grubisic, N. M. Gasperov, and M. Grce. 2009. Identification of human papillomavirus type 16 integration sites in high-grade precancers cervical lesions. Gynecol. Oncol. 113:120–127.
67. Luft, F., R. Klaes, M. Nees, M. Durst, V. Heilmann, P. Melsheimer, et al. 2001. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int. J. Cancer 92:9–17.
68. Li, H., Y. Yang, R. Zhang, Y. Cai, X. Yang, Z. Wang, et al. 2013. Preferential sites for the integration and disruption of human papillomavirus 16 in cervical lesions. J. Clin. Virol. 56(4):342–347. https://doi.org/10.1016/j.jcv.2012.12.014
69. De Marco, L., A. Gillio-Tos, L. Bonello, V. Ghisetti, G. Ronco, and F. Merletti. 2007. Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J. Clin. Virol. 38:7–13.
70. Yu, T., M. J. Ferber, T. H. Cheung, T. K. Chung, Y. F. Wong, and D. I. Smith. 2005. The role of viral integration in the development of cervical cancer. Cancer Genet. Cytogenet. 158:27–34.
71. Tsakogiannis, D., M. Bleta, Z. Kyriakopoulou, T. G. Dimitriou, C. Kotsovasillis, E. Panotopoulou, et al. 2016. Identification of rearranged sequences of HPV16 DNA in precancerous and cervical cancer cases. Mol. Cell. Probes 30:6–12.
72. Thorland, E. C., S. L. Myers, D. H. Persing, G. Sarkar, R. M. McGovern, B. S. Gostout, et al. 2000. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res. 60:5916–5921.
73. Thorland, E. C., S. L. Myers, B. S. Gostout, and D. I. Smith. 2003. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22:1225–1237.
74. Wentzensen, N., R. Ridder, R. Klaes, S. Vinokurova, U. Schaefer, and M. K. Doeberitz. 2002. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 21:419–426.
75. Nakanishi, G., K. Fujii, K. Asagoe, T. Tanaka, and K. Iwatsuki. 2009. Human papillomavirus genome integration in multifocal vulvar Bowen’s disease and squamous cell carcinoma. Clin. Exp. Dermatol. 34:e965–e967.
76. Kraus, L., C. Driesch, S. Vinokurova, E. Hovig, A. Schneider, M. von Knebel Doeberitz, et al. 2008. The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res. 68:2514–2522.
77. Klimov, E., S. Vinokurovka, E. Moisjak, E. Rakhmanaliev, V. Koseva, L. Laimins, et al. 2002. Human papilloma viruses and cervical tumours: mapping of integration sites and analysis of adjacent cellular sequences. BMC Cancer 2:24.
78. Klaes, R., S. M. Woerner, R. Ridder, N. Wentzensen, M. Duerst, A. Schneider, et al. 1999. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 59:6132–6136.
79. Hafner, N., C. Driesch, M. Gajda, L. Jansen, R. Kirchmayr, I. B. Runnebaum, et al. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27:1610–1617.
80. Das, P., A. Thomas, U. Mahantshetty, S. K. Shrivastava, K. Deodhar, and R. Mulherkar. 2012. HPV genotyping and site of viral integration in cervical cancers in Indian Women. PLoS ONE 7:e41012.
81. Wentzensen, N., S. Vinokurova, and M. von Knebel Doeberitz. 2004. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64:3878–3884.
82. Dall, K. L., C. G. Scarpini, I. Roberts, D. M. Winder, M. A. Stanley, B. Muralidhar, et al. 2008. Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res. 68:8249–8259.
83. Becker, N. A., E. C. Thorland, S. R. Denison, L. A. Phillips, and D. I. Smith. 2002. Evidence that instability within the FRA3B region extends four megabases. Oncogene 21:8713–8722.

84. Peter, M., C. Rosty, J. Couturier, F. Radavanyi, H. Teshima, and X. Sastre-Garau. 2006. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene 25:5985–5993.

85. Adey, A., J. N. Burton, J. O. Kitzman, J. B. Hiatt, A. P. Lewis, B. K. Martin, et al. 2013. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature 500:207–211.

86. Schmitz, M., C. Driesch, K. Beer-Grondke, L. Jansen, I. B. Runnebaum, and M. Durst. 2012. Loss of gene function as a consequence of human papillomavirus DNA integration. Int. J. Cancer 131:E593–E602.

87. Gao, G., S. H. Johnson, J. L. Kasperbauer, B. W. Eckloff, N. M. Tombers, G. Vasmatzis, et al. 2013. Mate pair sequencing of oropharyngeal squamous cell carcinomas reveals that HPV integration occurs much less frequently than in cervical cancer. J. Clin. Virol. 59(3):195–200. https://doi.org/10.1016/j.jcv.2013.12.006

88. Xu, B., S. Chotewutmontri, S. Wolf, U. Klos, M. Schmitz, M. Durst, et al. 2013. Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS ONE 8:e66693.

89. Akagi, K., J. Li, T. R. Broutian, H. Padilla-Nash, W. Xiao, B. Jiang, et al. 2014. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 24:185–199.

90. Holmes, A., S. Lameiras, E. Jeannot, Y. Marie, L. Castera, X. Sastre-Garau, et al. 2016. Mechanistic signatures of HPV insertions in cervical carcinomas. Npj Genomic Med. 1:16004.

91. Ojesina, A. I., L. Lichtenstein, S. S. Freeman, C. S. Pedamallu, I. Imaz-Rosshandler, T. J. Pugh, et al. 2014. Landscape of genomic alterations in cervical carcinomas. Nature 506:371–375.

92. Spaans, V. M., M. D. Trietsch, A. A. Peters, M. Osse, N. Ter Haar, G. J. Fleuren, et al. 2015. Precise classification of cervical carcinomas combined with somatic mutation profiling contributes to predicting disease outcome. PLoS ONE 10:e0133670.

93. Frumovitz, M., J. K. Burzawa, L. A. Byers, Y. A. Lyons, P. Ramalingam, R. C. Coleman, et al. 2016. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol. Oncol. 141:588–591.

94. Vinothkumar, V., G. Arunkumar, S. Revathidevi, K. Arun, M. Manikandan, A. K. Rao, et al. 2016. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumour Biol. 37:7907–7913.

95. Muller, E., B. Brault, A. Holmes, A. Legros, E. Jeannot, M. Campitelli, et al. 2015. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Med. 4:1484–1493.

96. Xiang, L., J. Li, W. Jiang, X. Shen, W. Yang, X. Wu, et al. 2015. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget. 6:4968–4975.

97. Chakraborty, C., S. Dutta, N. Mukherjee, S. Samadder, A. Roychowdhury, A. Roy, et al. 2015. Inactivation of PTCH1 is associated with the development of cervical carcinoma: clinical and prognostic implication. Tumour Biol. 36:1143–1154.

98. Rizvi, M. M., M. S. Alam, S. J. Mehdi, A. Ali, and S. Batra. 2012. Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from Northern Indian population. Pathol. Oncol. Res. 18:309–313.

99. Janku, F., J. J. Lee, A. M. Tsimberidou, D. S. Hong, A. Naing, G. S. Falchook, et al. 2011. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6:e22769.

100. Pandey, S., R. D. Mittal, M. Srivastava, K. Srivastava, S. Singh, S. Srivastava, et al. 2009. Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol. Oncol. 114:501–505.

101. Wright, A. A., B. E. Howitt, A. P. Myers, S. E. Dahlberg, E. Palescandolo, P. Van Hummelen, et al. 2013. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783.

102. Spaans, V. M., M. D. Trietsch, S. Crobach, E. Stelloo, D. Kremer, E. M. Osse, et al. 2014. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS ONE 9:e93451.

103. LE Inaki, K. 2012. Structural mutations in cancer: mechanistic and functional insights. Trends Genet. 28:550–559.

104. El Hamdani, W., M. Amrani, M. Attaleb, N. Laantri, M. M. Ennaji, M. Khyatti, et al. 2012. Loss of gene function as a consequence of human papillomavirus integration. Int. J. Cancer. 59(3):195–200. https://doi.org/10.1016/j.jcv.2013.12.006

105. Verlaat, W., P. J. Snijders, M. I. van Moorsel, M. I. van der Velden, A. W. van Santvoort, J. A. Weening, et al. 2013. Genomic alterations in cervical cancer specimens from Moroccan women. Cell Mol. Biol. (Noisy- le- grand) 56 Suppl:OL1373–OL1384.

106. Tornesello, M. L., C. Annunziata, L. Buonaguro, S. Losito, S. Greggi, and F. M. Buonaguro. 2014. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J. Transl. Med. 12:255.
107. Mazumder Indra, D., S. Mitra, R. K. Singh, S. Dutta, A. Roy, R. K. Mondal, et al. 2011. Inactivation of CHEK1 and EL24 is associated with the development of invasive cervical carcinoma: clinical and prognostic implications. Int. J. Cancer 129:1859–1871.

108. Mitra, S., D. Mazumder Indra, P. S. Basu, R. K. Mondal, A. Roy, S. Roychoudhury, et al. 2012. Alterations of RASSF1A in premalignant cervical lesions: clinical and prognostic significance. Mol. Carcinog. 51:723–733.

109. Goia-Rusanu, C. D., I. V. Iancu, A. Botezatu, D. Socolov, I. Huica, A. Plesa, et al. 2011. Mitochondrial DNA mutations in patients with HRHPV-related cervical lesions. Roum. Arch. Microbiol. Immunol. 70:5–10.

110. Dockter, J., A. Schroder, B. Eaton, A. Wang, N. Sikhamsay, L. Morales, et al. 2009. Analytical characterization of the APTIMA HPV Assay. J. Clin. Virol. 45(Suppl 1):S39–S47.

111. Xiang, L., W. Jiang, J. Li, X. Shen, W. Yang, G. Yang, et al. 2015. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci. Rep. 5:14035.

112. Wegman, P., C. Ahlin, and B. Sorbe. 2011. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. Int. J. Gynecol. Cancer 21:86–91.

113. Bird, A. P. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209–213.

114. Yuan, J., W. Jiang, J. Li, X. Shen, W. Yang, G. Yang, et al. 2015. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci. Rep. 5:14035.

115. Bird, A. P. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209–213.

116. Qiu, S., M. Martinez-Salazar, V. M. Galvan, R. Mendez, G. T. Diaz-Contreras, M. Alvarado-Hermida, et al. 2011. Analysis of CpG methylation sites and CGI among human papillomavirus DNA genomes. BMC Genom. 12:580.

117. Clarke, M. A., N. Wentzensen, L. Mirabello, A. Ghosh, S. Wacholder, A. Harari, et al. 2012. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol. Biomarkers Prev. 21:2125–2137.

118. Ding, D. C., M. H. Chiang, H. C. Lai, C. A. Hsiung, C. Y. Hsieh, and T. Y. Chu. 2009. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 147:215–220.

119. Wentzensen, N., C. Sun, A. Ghosh, W. Kinney, L. Mirabello, S. Wacholder, et al. 2012. Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. JNCI 104:1738–1749.

120. Frimer, M., C. Sun, T. McAndrew, B. Smith, A. Harari, Z. Chen, et al. 2015. HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study. Gynecol. Oncol. 138:94–100.

121. Liu, P., M. Iden, S. Fye, Y. W. Huang, E. Hopp, C. Chu, et al. 2017. Targeted, deep sequencing reveals full methylation profiles of multiple HPV types and potential biomarkers for cervical cancer progression. Cancer Epidemiol. Biomarkers Prev. 26:642–650.

122. Au Yeung, C. L., W. P. Tsang, T. Y. Tsang, N. N. Co, P. L. Yau, and T. T. Kwok. 2010. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol. Rep. 24:1599–1604.

123. Li, L., C. Xu, J. Long, D. Shen, W. Zhou, Q. Zhou, et al. 2015. E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines. Oncotarget. 6:23930–23943.

124. Hesselink, A. T., D. A. Heideman, R. D. Steenbergen, V. M. Coupe, R. M. Overmeer, D. Rijkaart, et al. 2011. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin. Cancer Res. 17:2459–2465.

125. Bierkens, M., A. T. Hesselink, C. J. Meijer, D. A. Heideman, G. B. Wisman, A. G. van der Zee, et al. 2013. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int. J. Cancer 133:1293–1299.

126. van Baars, R., J. van der Marel, P. J. Snijders, A. Rodriguez-Manfredi, B. ter Harmsel, H. A. van den Munckhof, et al. 2016. CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. Int. J. Cancer 138:463–471.

127. Lando, M., C. S. Fjeldbo, S. M. Witting, B. C. Snoek, E. K. Aarnes, M. F. Forberg, et al. 2015. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer. Epigenetics 10:970–980.

128. Su, P. H., Y. W. Lin, R. L. Huang, Y. P. Liao, H. Y. Lee, H. C. Wang, et al. 2013. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene 32:15–26.

129. Yin, F. F., N. Wang, X. N. Bi, X. Yu, X. H. Xu, Y. L. Wang, et al. 2016. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16
oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer. Virol. J. 13:60.

130. Rizvi, M. M., M. S. Alam, A. Ali, S. J. Mehdi, S. Batra, and A. K. Mandal. 2011. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J. Cancer Res. Clin. Oncol. 137:1255–1262.

131. Yu, M. Y., J. H. Tong, P. K. Chan, T. L. Lee, M. W. Chan, A. W. Chan, et al. 2003. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int. J. Cancer 105:204–209.

132. Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, et al. 2017. Integrated genomic and molecular characterization of cervical cancer. Nature 543:378–384.

133. Meijer, C., and R. D. M. Steenbergen. 2017. Gynaecological cancer: Novel molecular subtypes of cervical cancer - potential clinical consequences. Nat. Rev. Clin. Oncol. 14:397–398.

134. Wilting, S. M., and R. D. M. Steenbergen. 2016. Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res. 2:85–88.

135. Mirnezami, R., J. Nicholson, and A. Darzi. 2012. Preparing for precision medicine. N. Engl. J. Med. 366:489–491.

136. Baer, A., N. B. Kiviat, S. Kulasingam, C. Mao, J. Kuypers, and L. A. Koutskey. 2002. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet. Gynecol. 99:1053–1059.

137. Papanicolaou, G. N., and H. F. Traut. 1997. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch. Pathol. Lab. Med. 121:211–224.

138. National Cancer Institute Workshop. 1989. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 262:931–934.

139. Committee on Practice B-G. 2012. ACOG practice bulletin number 131: Screening for cervical cancer. Obstet. Gynecol. 120:1222–1238.

140. Wright, T. C., M. H. Stoler, C. M. Behrens, A. Sharma, G. Zhang, and T. L. Wright. 2015. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136:189–197.

141. Sankaranarayanan, R., B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, A. M. Budukh, et al. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385–1394.

142. FDA approves first human papillomavirus test for primary cervical cancer screening [news release]. U S Food and Drug Administration. (Accessed April 24, 2014.).

143. The American College of Obstetricians and Gynecologists. 2016. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. Obstet. Gynecol. 127:e1–e20.

144. Huh, W. K., K. A. Ault, D. Chelmow, D. D. Davey, R. A. Goulart, F. A. Garcia, et al. 2015. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet. Gynecol. 125:330–337.

145. Bobdey, S., J. Sathwara, A. Jain, and G. Balasubramianam. 2016. Burden of cervical cancer and role of screening in India. Indian J. Med. Paediatr. Oncol. 37:278–285.

146. Di, J., S. Rutherford, and C. Chu. 2015. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac. J. Cancer Prev. 16:7401–7407.

147. Wentzensen, N., M. Schiffman, T. Palmer, and M. Arbyn. 2016. Triage of HPV positive women in cervical cancer screening. J. Clin. Virol. 76(Suppl 1):S49–S55.

148. Balthz, N., K. Sundstrom, J. F. Nygard, J. Dillner, and J. Komorowski. 2017. Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population. Int. J. Cancer 141:200–209.

149. Hu, B., N. Tao, F. Zeng, M. Zhao, L. Qiu, W. Chen, et al. 2014. A risk evaluation model of cervical cancer based on etiology and human leukocyte antigen allele susceptibility. Int. J. Infect. Dis. 28:8–12.

150. Kim, J. J., E. A. Burger, S. Sy, and N. G. Campos. 2017. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J. Natl Cancer Inst. 109(2):djw216.

151. Giorgi Rossi, P., F. Carozzi, A. Federici, G. Ronco, M. Zappa, S. Franceschi, et al. 2017. Cervical cancer screening in women vaccinated against human papillomavirus: Recommendations from a consensus conference. Prev. Med. 98:21–30.

152. Poljak, M., B. J. Kocjan, A. Ostrbenk, and K. Seme. 2016. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J. Clin. Virol. 76(Suppl 1):S3–S13.

153. Wright, T. C. Jr, M. Schiffman, D. Solomon, J. T. Cox, F. Garcia, S. Goldie, et al. 2004. Interim consensus conference. Prev. Med. 33:339–344.

154. Ginocchio, C. C., D. Barth, and F. Zhang. 2008. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46:1641–1646.
155. Schutzbank, T. E., C. Jarvis, N. Kahmann, K. Lopez, M. Weimer, and A. Yount. 2007. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J. Clin. Microbiol. 45:4067–4069.

156. Stillman, M. J., S. P. Day, and T. E. Schutzbank. 2009. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus. J. Clin. Virol. 45(Suppl 1):S73–S77.

157. Heideman, D. A., A. T. Hesselink, J. Berkhof, W. J. Melchers, N. F. Daalmeijer, et al. 2011. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J. Clin. Microbiol. 49:3983–3985.

158. Stoler, M. H., T. C. Wright, Jr, A. Sharma, R. Apple, K. Gutekunst, T. L. Wright, et al. 2011. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 135:468–475.

159. Cui, M., N. Chan, M. Liu, K. Thai, J. Malaczynska, I. Consolaro. 2012. A review of methods for detecting high-risk human papillomavirus. Virol. J. 9:262.

160. Tjalma, W. A., and C. E. Depuydt. 2013. Cervical cancer screening: which HPV test should be used—L1 or E6/E7? Eur. J. Obstet. Gynecol. Reprod. Biol. 170:45–46.

161. Sauter, J. L., S. L. Mount, T. L. St John, C. M. Wojewoda, R. J. Bryant, and G. Leiman. 2014. Testing for integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care? Acta Cytol. 58:162–166.

162. Klet, B., L. J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, et al. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 155:1731–1739.

163. Brink, A. A., P. J. Snijders, and C. J. Meijer. 2007. HPV detection methods. Dis. Markers 23:273–281.

164. Abreu, A. L., R. P. Souza, F. Gimenes, and M. E. Consolario. 2012. A review of methods for detect human Papillomavirus infection. Virol. J. 9:262.

165. Mendez, F., N. Munoz, H. Posso, M. Molano, V. Moreno, A. J. van den Brule, et al. 2005. Cervical infection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 192:1158–1165.

166. Trotter, H., S. Mahmud, M. C. Costa, J. P. Sobrinho, E. Duarte-Franco, T. E. Rohan, et al. 2006. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 15:1274–1280.

167. Li, W., X. Zeng, N. P. Lee, X. Liu, S. Chen, B. Guo, et al. 2013. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics 102:338–344.

168. Ameur, A., T. L. Meiring, I. Bunikis, S. Haggqvist, C. Lindau, J. H. Lindberg, et al. 2014. Comprehensive profiling of the vaginal microbiome in HIV positive women using massive parallel semiconductor sequencing. Sci. Rep. 4:4398.

169. Johansson, H., D. Bzhalava, J. Ekstrom, E. Hultin, J. Dillner, and O. Forslund. 2013. Metagenomic sequencing of “HPV-negative” condylomas detects novel putative HPV types. Virology 440:1–7.

170. Bernard, H. U., S. Y. Chan, M. M. Manos, C. K. Ong, L. L. Villa, H. Delius, et al. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J. Infect. Dis. 170:1077–1085.

171. de Villiers, E. M., C. Fauquet, T. R. Broker, H. U. Bernard, and H. Zur Hausen. 2004. Classification of papillomaviruses. Virology 324:17–27.

172. Barzon, L., V. Miliotello, E. Lavezzo, E. Franchin, E. Peta, L. Squarzon, et al. 2011. Human papillomavirus genotyping by 454 next generation sequencing technology. J. Clin. Virol. 52:93–97.

173. Tennakoon, C., and W. K. Sung. 2015. BATVI: Fast, sensitive and accurate detection of virus integrations. BMC Bioinformatics 18(Suppl 3):71.

174. Chandrani, P., V. Kulkarni, P. Iyer, P. Upadhay, R. Chaudhary, P. Das, et al. 2015. NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome. Br. J. Cancer 112:1958–1965.

175. Li, J. W., R. Wan, C. S. Yu, N. N. Co, N. Wong, and T. F. Chan. 2013. ViralFusionSeq: accurately discover viral integration events and reconstruct fusion transcripts at single-base resolution. Bioinformatics 29:649–651.

176. Ho, D. W., K. M. Sze, and I. O. Ng. 2015. Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability. Oncotarget. 6:20959–20963.

177. Wang, Q., P. Jia, and Z. Zhao. 2013. VirusFinder: software for efficient and accurate detection of viruses and their integration sites in host genomes through next generation sequencing data. PLoS ONE 8:e64465.

178. Chen, Y., H. Yao, E. J. Thompson, N. M. Tannir, J. N. Weinstein, and X. Su. 2013. VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics 29:266–267.
179. Forster, M., S. Szymczak, D. Ellinghaus, G. Hemmrich, M. Ruhlemann, L. Kraemer, et al. 2015. Vy-PER: eliminating false positive detection of virus integration events in next generation sequencing data. Sci. Rep. 5:11534.

180. Militello, V., E. Lavezzo, G. Costanzi, E. Franchin, B. Di Camillo, S. Toppo, et al. 2013. Accurate human papillomavirus genotyping by 454 pyrosequencing. Clin. Microbiol. Infect. 19:E428–E434.

181. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9–29.

182. Smola, S.. 2017. Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy. Viruses 9(9):E254. https://doi.org/10.3390/v9090254

183. Tewari, K. S., M. W. Sill, H. J. Long, 3rd, R. T. Penson, H. Huang, L. M. Ramondetta, et al. 2014. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370:734–743.

184. Petit, R. G., A. Mehta, M. Jain, S. Gupta, R. Nagarkar, V. Kumar, et al. 2014. ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer. J. ImmunoTherapy Cancer 2(Suppl 3):P92.

185. Stevanovic, S., L. M. Draper, M. M. Langhan, T. E. Campbell, M. L. Kwong, J. R. Wunderlich, et al. 2015. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33:1543–1550.

186. Frenel, J.-S., C. L. Tourneau, B. H. O’Neil, P. A. Ott, S. A. Piha-Paul, C. A. Gomez-Roca, et al. 2016. Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. J. Clin. Oncol. 34(Suppl 15):5515.

187. Periwal, V. A.. 2016. Comprehensive overview of computational resources to aid in precision genome editing with engineered nucleases. Brief. Bioinform. 18(4):698–711.

188. Mali, P., L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, et al. 2013. RNA-guided human genome engineering via Cas9. Science 339:823–826.

189. Fu, Y., J. A. Foden, K. Khayter, M. L. Maeder, D. Reyon, J. K. Joung, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31:822–826.

190. Ran, F. A., P. D. Hsu, C. Y. Lin, J. S. Gootenberg, S. Konermann, A. E. Trevino, et al. 2013. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380–1389.

191. Hodge, L. S., L. S. Downs, Jr, J. C. Chura, S. G. Thomas, P. S. Callery, A. P. Soisson, et al. 2012. Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol. Oncol. 127:121–125.

192. Caramella, C. M., S. Rossi, F. Ferrari, M. C. Bonfferoni, and G. Sandri. 2015. Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv. Drug Deliv. Rev. 92:39–52.

193. D’Cruz, O. J., P. Samuel, B. Waurzyniak, and F. M. Uckun. 2003. Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Biol. Reprod. 69:1843–1851.

194. Coote, J. H., and M. J. Joyner. 2015. Is precision medicine the route to a healthy world? Lancet 385:1617.